FAQ

Anti-EGFR Monoclonal Antibody Mixture Sym004

Known as: Futuximab/Zatuximab, Sym004 
A mixture of two recombinant IgG1 antibodies directed against different epitopes in the epidermal growth factor receptor (EGFR) extracellular domain… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2010-2017
02420102017

Related topics

Related topics

1 relation
antigen binding

Related mentions per year

Related mentions per year

1957-2018
1960198020002020
Anti-EGFR Monoclonal Antibody Mixture Sym004
antigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer.
PURPOSE Approved anti-EGFR antibodies cetuximab and panitumumab provide significant clinical benefit in patients with metastatic… (More)
  • table 1
  • table 2
Is this relevant?
2016
2016
Colorectal and gastric cancer in 2015: The development of new agents and molecular classifications
 
Is this relevant?
2015
2015
Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer.
UNLABELLED Tumor growth in the context of EGFR inhibitor resistance may remain EGFR-dependent and is mediated by mechanisms… (More)
Is this relevant?
2015
2015
Sym004: Truly a New Level of Anti-EGFR Treatment?
Sym004 is a new antibody mixture to target EGFR in metastatic colorectal cancer. Preclinical data suggest efficacy in anti-EGFR… (More)
  • figure 1
Is this relevant?
2015
2015
A proof of concept trial of the anti-EGFR antibody mixture Sym004 in patients with squamous cell carcinoma of the head and neck
The purpose of the trial was to assess the efficacy and tolerability of Sym004, a novel 1:1 mixture of two chimeric monoclonal… (More)
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2013
2013
Sym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximab.
The epidermal growth factor receptor (EGFR) is a central regulator of tumor progression in a variety of human cancers. Cetuximab… (More)
Is this relevant?
2013
2013
Sym004, a novel anti-EGFR antibody mixture, augments radiation response in human lung and head and neck cancers.
Sym004 represents a novel EGF receptor (EGFR)-targeting approach comprising a mixture of two anti-EGFR antibodies directed… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2011
2011
Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor.
The epidermal growth factor receptor (EGFR) is frequently dysregulated in human malignancies and a validated target for cancer… (More)
Is this relevant?
2011
2011
Preclinical pharmacokinetics and safety of Sym004: a synergistic antibody mixture directed against epidermal growth factor receptor.
PURPOSE Sym004 is a novel therapeutic antibody mixture product comprising two unmarketed monoclonal antibodies (mAb) targeting… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2010
Highly Cited
2010
Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy.
Epidermal growth factor receptor (EGFR) is a validated therapeutic target in cancer and EGFR antagonists with greater… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?